Clin Oncol (R Coll Radiol) 2017 Oct 13
UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy.
Abstract
Six UK studies investigating stereotactic ablative radiotherapy (SABR) are currently open. Many of these involve the treatment of oligometastatic disease at different locations in the body. Members of all the trial management groups collaborated to generate a consensus document on appropriate organ at risk dose constraints. Values from existing but older reviews were updated using data from current studies. It is hoped that this unified approach will facilitate standardised implementation of SABR across the UK and will allow meaningful toxicity comparisons between SABR studies and internationally.
Related Questions
What dose constraints do you use for RCC/Kidney SBRT?
As is often the case, there is no single answer to this question, and the ALARA principle should always be kept in mind. A good starting place to determine your OAR constraints for a given case is to consider the clinical context. Ultimately, in deciding on allowable OAR constraints, one has to cons...
How would you manage a metastatic lesion abutting the optic structures (globe, optic nerve, etc)?
Generally, if I'm treating a metastatic lesion abutting an OAR - in this case, it's an optic nerve - I try to keep my Dmax to the optic nerve/chiasm to 8 Gy (allow up to 10 Gy if needed). If I can't achieve those constraints, I would favor fractionated radiosurgery. There are some papers looking at ...
For a patient with a solitary kidney, what dose constraints would you use for SBRT to a nearby site?
I use the UK Consensus on Normal Tissue Dose Constraints for SRS & SBRT.For a solitary kidney, the SBRT 5 fxn OAR constraint is Mean <10 Gy V10 Gy <10% (optimal), but can go up to <45% (mandatory) This is based on the ABC-07 & SPARC trial protocols.
Do you have a size limitation (e.g. >3cm) for offering SRS for pituitary adenomas if OAR tolerances can otherwise be respected?
While pituitary adenoma size plays a role in my decision making for SRS, I would also take into account dose constraints to the optic apparatus. For single fraction, I like to keep my optic nerve and chiasm max dose under 8 Gy. If I am unable to achieve that, I would consider hypofractionation in 3 ...
What dose-volume constraint should be used for the normal brain parenchyma in a patient receiving 5-fraction SBRT?
This is tough, because most of the literature is based upon single fraction SRS for 1-3 lesions. There are no one criteria for brain doses for multi-session treatments as stated above. Tumor coverage is most paramount, and I agree with the need to respect the adjacent structure doses and to optimize...